edna: <<Stay on the roller coaster to 70.>> Sounds mighty good to me!!! I'm with you.
Incidentally, CORR got banged on 1/29 (partial publication):
<<<Samad said the panel took issue with COR's data showing
that in its so-called PURSUIT study of almost 11,000 patients
with unstable angina, Integrilin reduced the rate of death or
serious heart attack from 15.7 percent to 14.2 percent.
"The panel felt the way COR did its statistical analysis
was not done properly," he said, and thus failed to show
statistically significant efficacy for the angina patients.
And although the panel did recommend the drug for patients
undergoing angioplasty procedures, Samad said it cited serious
concern about bleeding at the dose preferred by COR.
"There was heated debate about the dosing issue," he said,
with COR arguing that the lower dose suggested by the FDA panel
had sub-optimal therapeutic benefits. The FDA almost always
follows the recommendations of its advisory panels.
If the FDA follows the panel's recommendation and approves
Integrilin for angioplasty, a procedure in which surgeons
insert a small balloon to stretch out blocked arteries, it
would compete head-on with Centocor Inc (NASDAQ:CNTO) anti-platelet
drug ReoPro.
ReoPro, marketed by Eli Lilly and Co (NYSE:LLY) for both
angioplasty and unstable angina, had revenues in 1997 of about
$250 million, Samad said, mostly from angioplasty patients.>>
--------------------------------------------------------------
I believe a previous post indicated that Reopro was not approved for unstable angina! Am I missing something??? My understanding is the CNTO got expanded use of Reoproas, as indicated above. (Someone help!)
Incidentally, the the daily closing 3-month chart still maintains CNTO in uptrend. While the next few weeks may be shaky, there is support at 42 and 40...shakeout can be expected, so hold on, that is you believe Reopro is the drug of choice (IMHO).
Good luck,
FNS
|
